For the cumulative third quarter of FY2025, revenue was 1,533.5 billion yen (YoY +12.1%), operating income was 233.8 billion yen (YoY -5.9%), and net income attributable to owners of parent was 217.4 billion yen (YoY +4.2%).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4568-20260130-02.pdf","jir_short_summary":"For the cumulative third quarter of FY2025, revenue was 1,533.5 billion yen (YoY +12.1%), operating income was 233.8 billion yen (YoY -5.9%), and net income attributable to owners of parent was 217.4 billion yen (YoY +4.2%).","jir_summary":"### Summary of Financial Results\nFor the cumulative third quarter of FY2025, revenue amounted to 1,533.5 billion yen, representing a 12.1% increase year-over-year. Operating income was 233.8 billion yen, down 5.9% year-over-year; however, core operating income increased by 8.8% year-over-year to 249.2 billion yen, indicating an improvement in recurring profitability. Net income attributable to owners of parent rose 4.2% year-over-year to 217.4 billion yen. The overseas sales ratio remained high at 70.2%. Sales of key global products, including the anticancer agent trastuzumab deruxtecan (Enhertu) and Daturway, performed well, particularly with strong growth in the U.S. market.\n\n### Financial Position and Cash Flow\nAs of the end of December 2025, total assets were 3,821.8 billion yen, an increase of 365.7 billion yen compared to the end of the previous fiscal year. Current assets stood at 2,095.2 billion yen and non-current assets at 1,726.6 billion yen. Interest-bearing debt increased by 195.3 billion yen to 351.2 billion yen year-over-year, reducing net cash to 327.9 billion yen. Cash flow from operating activities was positive 51.7 billion yen, cash flow from investing activities was negative 159.7 billion yen, and cash flow from financing activities was positive 0.4 billion yen. Free cash flow totaled negative 108.0 billion yen.","jir_financial_highlights":"Revenue: 1,533.5 billion yen (YoY +12.1%)\nOperating Income: 233.8 billion yen (YoY -5.9%)\nNet Income Attributable to Owners of Parent: 217.4 billion yen (YoY +4.2%)\nCore Operating Income: 249.2 billion yen (YoY +8.8%)\nOverseas Sales Ratio: 70.2% (Unknown)","jir_category":"","jir_hashtags":"#DaiichiSankyo, #SupplementaryFinancialInformation, #JapaneseStocks","jir_key_figures":"Revenue: 1,533.5 billion yen (YoY +12.1%)\nOperating Income: 233.8 billion yen (YoY -5.9%)\nNet Income Attributable to Owners of Parent: 217.4 billion yen (YoY +4.2%)","jir_meta_title":"Daiichi Sankyo FY2025 Third Quarter Supplementary Financial Information Revenue 1,533.5 billion yen, Operating Income 233.8 billion yen","jir_meta_description":"Daiichi Sankyo Company, Limited\u2019s FY2025 third quarter supplementary financial information reports revenue of 1,533.5 billion yen (YoY +12.1%), operating income of 233.8 billion yen (YoY -5.9%), and net income of 217.4 billion yen (YoY +4.2%). Strong performance from key products contributed to results.","jir_og_title":"Daiichi Sankyo FY2025 Third Quarter Supplementary Financial Information Released","jir_og_description":"Revenue of 1,533.5 billion yen, operating income of 233.8 billion yen, net income of 217.4 billion yen. Growth in key products supports performance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (FY2020 to FY2025 Third Quarter Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2020\\\",\\\"FY2021\\\",\\\"FY2022\\\",\\\"FY2023\\\",\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (billion yen)\\\",\\\"data\\\":[10420,13160,15840,18480,19500,15335],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (FY2024-FY2025 Third Quarter Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024 Third Quarter\\\",\\\"FY2025 Third Quarter\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (billion yen)\\\",\\\"data\\\":[2483,2338],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Income Trend (FY2024-FY2025 Third Quarter Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024 Third Quarter\\\",\\\"FY2025 Third Quarter\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income (billion yen)\\\",\\\"data\\\":[2290,2492],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Share in FY2025 Third Quarter Cumulative\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan Business Unit\\\",\\\"Oncology Business Unit\\\",\\\"American Regent Unit\\\",\\\"EU Specialty Business Unit\\\",\\\"ASCA Business Unit\\\"],\\\"datasets\\\":[{\\\"data\\\":[4792,6036,1798,2001,1872],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\",\\\"#dc3545\\\",\\\"#6f42c1\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"cash_flow_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Cash Flow from Operating, Investing, and Financing Activities (FY2024-FY2025 Third Quarter Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Operating Activities CF\\\",\\\"Investing Activities CF\\\",\\\"Financing Activities CF\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2024 Third Quarter\\\",\\\"data\\\":[-183,3671,-3193],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"FY2025 Third Quarter\\\",\\\"data\\\":[517,-1597,4],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22164","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n